You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 124 No. 12, December 1988 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  STUDIES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (76)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Interleukin 2 and Psoriasis

Roberta E. Lee, MD; Anthony A. Gaspari, MD; Michael T. Lotze, MD; Alfred E. Chang, MD; Steven A. Rosenberg, MD, PhD

Arch Dermatol. 1988;124(12):1811-1815.


Abstract



• Immunotherapy with interleukin 2 and lymphokineactivated killer cells can result in regression of metastatic cancer. Dermatologic complications associated with this therapy include erythema, pruritus, and a mild desquamation. Three patients with a history of psoriasis received high-dose interleukin 2 alone or in conjunction with lymphokine-activated killer cells for treatment of metastatic renal cell carcinoma. Two patients developed an erythrodermic exacerbation during therapy while the third patient experienced a localized flare. Topical treatment was effective in inducing remission in all three patients. Histologic analysis of serial skin biopsy specimens revealed psoriasiform changes in involved skin as well as epidermal spongiosis and a perivascular mononuclear cell infiltrate. The psoriatic exacerbation from interleukin 2 did not affect antitumor response to the therapy and should not be considered a contraindication to treatment.

(Arch Dermatol 1988;124:1811-1815)



Author Affiliations



From the Surgery (Drs Lee, Lotze, Chang, and Rosenberg) and Dermatology Branches (Dr Gaspari), National Cancer Institute, National Institutes of Health, Bethesda, Md. Dr Lee is now with the Division of General Surgery, Stanford (Calif) University Hospital, Stanford University Medical Center.


Footnotes



Accepted for publication June 24, 1988.

Reprint requests to Surgery Branch, National Cancer Institute, Bldg 10, Room 2B42, National Institutes of Health, Bethesda, MD 20892 (Dr Rosenberg).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Autoimmunity as a Complication of Interleukin 2 Immunotherapy: Many Unanswered Questions
Gaspari
Arch Dermatol 1994;130:894-898.
ABSTRACT  

T-Cell Activation Is Potentiated by Cytokines Released by Lesional Psoriatic, but Not Normal, Epidermis
Chang et al.
Arch Dermatol 1992;128:1479-1485.
ABSTRACT  

The Cytokine Network in Psoriasis
Nickoloff
Arch Dermatol 1991;127:871-884.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.